Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. - This inclusion b...
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023
* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors * The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical canc...
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hemato...
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. * The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolo...
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. - The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolog...
Antengene Announces NDA Submission for XPOVIO® in Indonesia
SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO
SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announ...
Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting
* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-008 (mTORC1/2 inhibitor), ATG-017 (ERK1/2 inhibitor), ATG-037 (CD73 inhibitor), ATG-031 (anti-CD24 monoclonal antibody) and ATG-034 (LILRB4 antagonist antibody) * Clinical results showed promising ...
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. * The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in p...
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022. 1. Sales Revenue Reached 5.6 Times Year-Over-Year ...
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
– Five posters will showcase progress with multiple preclinical and clinical programs, including the clinical results ofATG-008 (mTORC1/2 inhibitor) and preclinical data ofATG-031 (anti-CD24 monoclonal antibody), ATG-037 (small molecule CD73 inhibitor), ATG-017 (ERK1/2 inhibitor), and ATG-034 (L...
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China
- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. - The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in pat...
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)
- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy - The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors...
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors
* Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting the Tumor Associated Antigen (TAA) Claudin 18.2 * The Phase I trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 as a monotherapy in patients withadvanced or...
Antengene Appoints Amily Zhang as its Chief Medical Officer
SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
* An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status * Study builds on promising results of Phase II TORCH monotherapy study in HBV+ p...
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 - Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeutic option for heavily pre-treated Stage III/IV patients with relapsed/refractory (R/R) T and NK-cell lymphoma - Online abstract with results from the open-label LAUNCH study demonstrated the encoura...
